Xencor | Spese Di Vendita E Di Amministrazione



Selling And Administration Expenses Cambiamento Data
AbbVie USD 3.86B 306M 2024-12
Alnylam Pharmaceuticals USD 295.34M 74.35M 2024-12
Amgen USD 1.88B 253M 2024-12
Arrowhead Research USD 30.2M 1.91M 2024-12
AstraZeneca USD 5.55B 307M 2024-12
Biogen USD 677.3M 99.6M 2024-12
Bristol-Myers Squibb USD 2.1B 129M 2024-12
Cytokinetics USD 62.34M 5.69M 2024-12
GlaxoSmithKline GBP 2.66B 1.14B 2024-12
J&J USD 6.45B 975M 2024-12
MacroGenics USD 27.81M 13.71M 2024-12
Merck USD 2.85B 148M 2024-12
Novartis USD 3.5B 368M 2024-12
Pfizer USD 4.27B 1.06B 2024-12
Regeneron Pharmaceuticals USD 792.2M 77.8M 2024-12
Roche Holding CHF 3.61B 381M 2024-12
Xencor USD 14.92M 148K 2024-12



Xencor Spese Di Vendita E Di Amministrazione - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Apr 2025.